Unichem climbs up by 5 per cent on ANDA approval

Unichem climbs up by 5 per cent on ANDA approval

Geyatee Deshpande
/ Categories: Trending, DSIJ News

 
Unichem Laboratories received a receipt of ANDA approval from the United States Food and Drug Administration (USFDA) for Unichem's Atenolol Tablets USP, 25 mg, 50 mg, and 100 mg. Reacting to the news, the stock climbed by 5.21 per cent.
 
Unichem Laboratories’ Atenolol Tablets USP, 25 mg, 50 mg, and 100 mg, are the generic version of TENORMIN (Atenolol) Tablets, 25 mg, 50 mg, and 100 mg, of Alvogen Malta Operations Ltd. These tablets are intended for the treatment of hypertension in lowering blood pressure. The company also announced that the product will be commercialized from Unichem's plant located in Ghaziabad.
 
Unichem Laboratories Limited is an internationally integrated, specialty pharmaceutical company that manufactures and markets a large basket of pharmaceutical formulations, including branded generics and generics in several markets across the world. In India, the company portrays strong skills in product development, process chemistry, and manufacturing complex API and dosage forms.
 
On Monday around 10:30 am, the stock of the company was trading at Rs. 160.75, up by 5.27 per cent or Rs. 8.05 per share. The 52-week high is Rs. 224.55 and the 52-week low is Rs. 141.75 on BSE.

Previous Article Stock of MEP Infra trades in green after receiving LOA
Next Article Ten stocks close to their 52-week high
Rate this article:
4.0

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR